EPS for Chimerix, Inc. (CMRX) Expected At $-0.49; Brookfield Asset Management Has Cut By $75.66 Million Its Prologis (PLD) Holding

February 16, 2018 - By Marguerite Chambers

Brookfield Asset Management Inc decreased Prologis Inc (PLD) stake by 28.73% reported in 2017Q3 SEC filing. Brookfield Asset Management Inc sold 1.20M shares as Prologis Inc (PLD)’s stock rose 10.06%. The Brookfield Asset Management Inc holds 2.98 million shares with $189.04 million value, down from 4.18M last quarter. Prologis Inc now has $33.11 billion valuation. The stock increased 1.44% or $0.87 during the last trading session, reaching $61.41. About 3.05 million shares traded or 28.66% up from the average. Prologis, Inc. (NYSE:PLD) has risen 18.74% since February 16, 2017 and is uptrending. It has outperformed by 2.04% the S&P500.

Analysts expect Chimerix, Inc. (NASDAQ:CMRX) to report $-0.49 EPS on March, 1.They anticipate $0.17 EPS change or 53.13% from last quarter’s $-0.32 EPS. After having $-0.37 EPS previously, Chimerix, Inc.’s analysts see 32.43% EPS growth. The stock increased 0.41% or $0.02 during the last trading session, reaching $4.95. About 114,233 shares traded. Chimerix, Inc. (NASDAQ:CMRX) has risen 3.54% since February 16, 2017 and is uptrending. It has underperformed by 13.16% the S&P500.




Investors sentiment decreased to 1.16 in Q3 2017. Its down 0.10, from 1.26 in 2017Q2. It dived, as 33 investors sold PLD shares while 175 reduced holdings. 66 funds opened positions while 176 raised stakes. 495.40 million shares or 0.93% less from 500.06 million shares in 2017Q2 were reported. Convergence Partners Limited Liability owns 4,451 shares for 0.04% of their portfolio. Bourgeon Capital Management Limited has 43,825 shares for 1.64% of their portfolio. Ls Inv Ltd Liability Company accumulated 0.06% or 16,125 shares. Bedrijfstakpensioenfonds Voor De Media Pno reported 34,299 shares or 0.24% of all its holdings. Westover Capital Ltd Co has 9,605 shares. Bartlett And Ltd Liability Co holds 0% of its portfolio in Prologis, Inc. (NYSE:PLD) for 600 shares. Rafferty Asset Ltd Co owns 0.13% invested in Prologis, Inc. (NYSE:PLD) for 88,116 shares. American Century Cos Inc invested 0.13% of its portfolio in Prologis, Inc. (NYSE:PLD). 115,964 are held by Echo Street Cap Management Ltd Liability Corp. Louisiana State Employees Retirement System owns 33,200 shares for 0.1% of their portfolio. Exxonmobil Management Incorporated Tx has 0.16% invested in Prologis, Inc. (NYSE:PLD) for 97,126 shares. Cibc Mkts Inc holds 0.01% in Prologis, Inc. (NYSE:PLD) or 34,381 shares. Whittier Com Of Nevada holds 0.14% or 24,046 shares. 39,133 are held by Oppenheimer. Sumitomo Mitsui Tru Holding Incorporated has 0.17% invested in Prologis, Inc. (NYSE:PLD).

Among 26 analysts covering Prologis (NYSE:PLD), 14 have Buy rating, 1 Sell and 11 Hold. Therefore 54% are positive. Prologis had 69 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was initiated by BB&T Capital on Thursday, November 12 with “Hold”. On Wednesday, October 25 the stock rating was maintained by Bank of America with “Buy”. The stock of Prologis, Inc. (NYSE:PLD) earned “Neutral” rating by UBS on Friday, July 1. Capital One downgraded the shares of PLD in report on Wednesday, May 18 to “Equal-Weight” rating. The stock of Prologis, Inc. (NYSE:PLD) earned “Buy” rating by BTIG Research on Thursday, August 25. The firm has “Buy” rating by BMO Capital Markets given on Monday, September 11. The rating was maintained by Jefferies with “Hold” on Sunday, August 20. The firm has “In-Line” rating by Evercore given on Monday, September 25. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, October 21 report. Wells Fargo downgraded the stock to “Market Perform” rating in Monday, November 30 report.

Brookfield Asset Management Inc increased Union Pac Corp (NYSE:UNP) stake by 8,700 shares to 9,970 valued at $1.16M in 2017Q3. It also upped Enbridge Energy Partners LP (NYSE:EEP) stake by 208,200 shares and now owns 2.06M shares. Exxon Mobil Corp (NYSE:XOM) was raised too.

Investors sentiment increased to 1.08 in Q3 2017. Its up 0.24, from 0.84 in 2017Q2. It is positive, as 12 investors sold Chimerix, Inc. shares while 25 reduced holdings. 8 funds opened positions while 32 raised stakes. 33.85 million shares or 4.32% more from 32.45 million shares in 2017Q2 were reported. Wells Fargo And Co Mn accumulated 53,326 shares or 0% of the stock. Royal Bancorp Of Canada owns 3,813 shares. Panagora Asset Mngmt stated it has 208,549 shares. Bnp Paribas Arbitrage holds 0% or 4,518 shares in its portfolio. Leisure Mgmt holds 28,168 shares. Great West Life Assurance Can accumulated 4,500 shares. Parametric Associate Limited Liability Co reported 0% of its portfolio in Chimerix, Inc. (NASDAQ:CMRX). Citigroup owns 2,335 shares. State Common Retirement Fund has invested 0% in Chimerix, Inc. (NASDAQ:CMRX). Virginia Retirement Systems Et Al reported 0% stake. Axa stated it has 0.01% of its portfolio in Chimerix, Inc. (NASDAQ:CMRX). Glenmede Na, Pennsylvania-based fund reported 6,992 shares. Blackrock reported 0% stake. 13,842 are held by Employees Retirement Association Of Colorado. Invesco Ltd holds 0% or 102,561 shares in its portfolio.

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company has market cap of $233.28 million. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients , as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It currently has negative earnings. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.